OXY -SAR-001   Page i 
Version: 2.5 
0008_Protocol v2.5, 08- 03-18, AMD.docx  
CONFIDENTIAL  
Revised  version: v2.5 08- 03-18 CLINICAL RESEARCH PROTOCOL  OXY -SAR-001 
 
 
 
THE PHYSIOLOGIC EFFECTS OF  
INTRANASAL OXYTOCIN ON SARCOPENIC OBESITY 
  
  
 
IND Sponsor:  Sara Espinoza, MD. Principal Investigator  
Associate Professor, Department of Medicine 
The University of Texas Health Science Center at San Antonio  
(UTHealth San Antonio)  
Barshop Institute for Longevity and Aging Studies  
      7703 Floyd Curl Dr ive 
      Mail Code 7886  
      San Antonio, Texas 78229- 3900  
      (210) 617 -5197  
Funding Sponsor:  NIH/NCATS - Clinical Translational Science Award â€“ Institute for the 
Integration of Medicine and Science 
Study Product:  Intranasal Oxytocin (Syntocinon; Novartis -Switzerland)  
Protocol Number:  HSC20160661H ( initial approval  03/24/2017 ) 
IND Number:  IND# 132460- 0007  
NCT#:  [STUDY_ID_REMOVED] 
Clinical Sites:   
University of Texas Health Science 
Center at Houston (UTHealth)   
Principal Investigator:   
   Jessica Lee, MD  
  
University of Texas Medical Branch 
(UTMB ), Galveston   
Principal Investigator:   
  Elena Volpi, MD  
  
University of Texas Health Science 
Center at San Antonio (UTHSCSA)   
Principal Investigator:    
  Sara Espinoza, MD    
Coordinating Center   
Clinical Trials Express  
6410 Fannin Street  
UTPB1100.34 
Houston, TX 77030  
 
 
OXY -SAR-001   Page ii 
Version: 2.5 
0008_Protocol v2.5, 08- 03-18, AMD.docx  
CONFIDENTIAL  
Revised  version: v2.5 08- 03-18  
  
 
TABLE OF CONTENTS  
  
STUDY SUMMARY â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦ ..â€¦... 1 
1 INTRODUCTION â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦ â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦ â€¦â€¦â€¦ â€¦... 2 
 1.1 BACKGROUND â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦  2 
 1.2 SIGNIFICANCE â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦...  2 
 1.3 PRELIMINARY DATAâ€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦ ... 3 
 1.4 INVESTIGATIONAL AGENT â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦..  3 
 1.5 DOSE RATIONALE AND RISK/BENEFITS â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦ â€¦â€¦â€¦â€¦â€¦â€¦....  3 
2 STUDY  OBJECTIVE â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦.  3 
3 STUDY  DESIGN â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦  3 
 3.1 SUBJECTS â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦.. â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦ .â€¦.. 3 
 3.2 GENERAL DESIGN â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦.. â€¦... 4 
 3.3 STUDY ENDPOINTS â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦ â€¦â€¦â€¦â€¦... â€¦â€¦â€¦â€¦â€¦â€¦ ... 4 
 3.4 POTENTIAL RISKS TO SUBJE CT SAFETY â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦ ... 4 
4 SUBJECT  SELECTION  AND  WITHDRAWAL â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦ . 5 
 4.1 INCLUSION CRITERIA â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦ .â€¦ 5 
 4.2 EXCLUSION CRITERIA â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦  6 
 4.3 RECRUITMENT AND SCREENING â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦.â€¦â€¦..  6 
 4.4 EARLY WITHDRAWAL â€¦â€¦â€¦â€¦â€¦ â€¦â€¦â€¦â€¦ â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦. â€¦â€¦... ... 6 
5 STUDY  DRUG â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦.. ..... 7 
 5.1 DESCRIPTION â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦.. .. 7 
 5.2 TREATMENT REGIMEN â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦ â€¦â€¦â€¦... .. 7 
 5.3 PREPARATION AND ADMINISTRATION OF STUDY DRUGâ€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦ â€¦.. 7 
 5.4 PRIOR AND CONCOMITANT THERAPY â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦. â€¦. 8 
 5.5 PACKAGING â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦  8 
 5.6 RECEIPT , STORAGE , AND HANDLING OF STUDY DRUGâ€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦..  8 
6 STUDY  PROCEDURES â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦...  9 
 6.1 VISIT 1â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦ â€¦.â€¦â€¦. 9 
 6.2 VISIT 2â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦... â€¦..â€¦. 9 
 6.3 VISIT 3  / RANDOMI ZATION ..â€¦â€¦â€¦ ..â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦. â€¦. 10 
 6.4 VISIT 4â€¦â€¦â€¦â€¦ â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦. â€¦. 10 
OXY -SAR-001   Page iii 
Version: 2.5 
0008_Protocol v2.5, 08- 03-18, AMD.docx  
CONFIDENTIAL  
Revised  version: v2.5 08- 03-18  6.5 VISIT 5â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦.â€¦.  11 
 6.6 VISIT 6â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦.â€¦.  11 
 6.7 VISIT 7â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦.â€¦.  11 
 6.8 VISIT 8â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦.â€¦.  11 
7 STATISTICAL  PLAN â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦...  12 
 7.1 SAMPLE SIZE DETERMINATION â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦....  12 
 7.2 STATISTICAL METHODS â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦.â€¦â€¦..  13 
8 SAFETY  AND  ADVERSE  EVENTS â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦.â€¦.â€¦.  13 
 8.1 DEFINITIONS â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦.â€¦  13 
 8.2 RECORDING AND REPORTING OF ADVERSE EVENTS â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦.....  14 
 8.3 RECORDING AND REPORTING OF SAE/UPIRSOâ€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦..â€¦â€¦â€¦.  15 
 8.4 MEDICAL MONITORING â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦.  16 
 8.5 UNBLINDING â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦..  17 
 8.6 STOPPING RULES â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦.  17 
9 DATA  HANDLING  AND  RECORD  KEEPING â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦......  18 
 9.1 CONFIDENTIALITY â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦.  18 
 9.2 SOURCE DOCUMENTS â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦..  18 
 9.3 DATA MANAGEMENT â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦  18 
 9.4 RECORDS RETENTION â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦.â€¦...  18 
10 STUDY  MONITORING,  AUDITING,  AND  INSPECTING â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦....  19 
 10.1 STUDY MONITORING PLANâ€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦  19 
 10.2 AUDITING AND INSPECTING â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦..  19 
11 ETHICAL  CONSIDERATIONS â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦.â€¦...  20 
12 STUDY  FINANCES .................................................................................................  20 
 12.1 FUNDING SOURCE â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦.â€¦â€¦â€¦â€¦...  20 
 12.2 CONFLICT OF INTEREST â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦  20 
 12.3 SUBJECT STIPEND OR PAYMENTS â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦  20 
13 REFERENCES â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦.â€¦â€¦â€¦â€¦..  21 
14 ATTACHMENTS â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦  22 
 A. PLACEHOLDER FOR SAMPLE CONSENT FORMâ€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦  23 
 B. PLACEHOLDER FOR EVENT SCHEDULE â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦  24 
 C. PLACEHOLDER FOR DRUG SUPPLIER (VICTORIA APOTHEKE ZURICH /NOVARTIS ). 25 
 D. PLACEHOLDER FOR QUESTIONNAIRES AND INSTRUMENTS â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦  26 
 E. PLACEHOLDER FOR SUMMARY OF PROTOCOL REVISIONS  27-29 
 
  
OXY -SAR-001   Page iv 
Version: 2.5 
0008_Protocol v2.5, 08- 03-18, AMD.docx  
CONFIDENTIAL  
Revised  version: v2.5 08- 03-18  
List of Abbreviations  
 
 
 
  OGTT â€“ Oral Glucose Tolerance Test  
SPPB â€“ Short Physical Performance Battery  
SIADH â€“ Syndrome of Inappropriate Antidiuretic Hormone Secretion  
TUG â€“ Timed Up and Go  
Mini- Cog â€“ Mini- Cog test - Screening for Cognitive Impairment in Older Adults  
MoCA  â€“ Montreal Cognitive Assessment  
GDS â€“ Geriatric Depression Scale  
CES- D â€“ Centers for Epidemiologic Studies Depression Scale  
 Page 1 
OXY -SAR-001  
0008_Protocol v2.5, 08- 03-18, AMD.docx  Revised  version: v2.5 08- 03-18 
 
CONFIDENTIAL         Study Summary  
Title The Physiologic Effects of Intranasal Oxytocin on Sarcopenic Obesity  
Protocol Number  OXY -SAR-001 
Phase  II 
Methodology  Eligible subjects self -administer 24 IU intranasal oxytocin q.i.d.  for 8 weeks. 
The study will examine whether  the intervention will promote weight loss and 
preserve muscle mass, thereby preserving and/or improving physical function 
in older su bjects with sarcopenic obesity.  
Study Duration  12 weeks Â± 1 week  
Study Center(s)  UTHSCSA, UT Health (Houston), UTMB  (Galveston) 
Objective  1) To assess the effect of intranasal oxytocin administration on body weight, 
adiposity, muscle mass, and glucose tolerance in older adults.  
2) To assess the effect of intranasal oxytocin on physical function and 
physiologic parameters of insulin signaling, inflammation, and muscle 
regeneration in older adults.  
Number of Subjects  36 completers (3 sites, up to 15 at each site, allowing for attrition) 
Inclusion Criteria  Age â‰¥60 years  
BMI 30.0 -43.0 kg/m2 
Sedentary ( â‰¤2 strenuous exercise/week)  
Gait speed < 1 meter/second  
Exclusion Criteria  1) Diabetes with Hemoglobin A1c (HbA1c) â‰¥ 6.5 and/ or taking medications 
known to effect glucose homeostasis  
2) Significant heart disease (history of MI within the last year or New York Heart Classification grade III -IV) 
3) Poorly controlled hypertension (SBP > 170 or DBP >95 mm/Hg)  
4) Anemia (Hematocrit <34%)  
5) Renal Disease  (glomerular filtration rate [GFR] < 30 mL/min, abnormal 
serum sodium levels, â‰¥ 5 white blood cells or â‰¥ 5 red blood cells on 
urinalysis) , or physical exam findings  indicative of fluid imbalance; 
individuals with underlying disorder of sodium/water balance, such as SIADH, diabetes insipidus, or psychogenic polydipsia) 
6) Liver Disease (AST/ALT/AlkPhos > 2 x upper limit of normal)  
7) Use of systemic steroi d, androgens, or anti -coagulants  
8) Active/unstable conditions: inflammatory, thyroid , autoimmune, 
gastrointestinal (GI), hematologic, or neoplastic disorders  (Exclude 
subjects with clinical lab values outside the normal range (other than as 
specified above) ) 
9) Individuals with underlying seizure disorder or underlying neurologic 
disorder that increases seizure risk  
10) Cognitive impairment ( MiniCog <3), unstable mental illness  or GDS > 7 , 
substance abuse, or history of eating disorder  
Study Product, Dose, 
Route, Regimen Intranasal Oxytocin 24 IU self -administered q.i.d. (3 puffs each nostril 4x/day)  
for 8 weeks  
Statistical Methodology  Generalized linear mixed effects model will be used to evaluate the effect of oxytocin on the change of each continuous measure.  The effect of oxytocin will be assessed by whether the time by oxytocin interaction is significantly different from 0 with a 2- sided p- value<0.05  
 
 
2;<6$5  3DJH
9HUVLRQ
B3URWRFROY$0'GRF[
&21),'(17,$/
5HYLVHGYHUVLRQY ,QWURGXFWLRQ
7KLVGRFXPHQWLVDSURWRFROIRUDKXPDQUHVHDUFKVWXG\7KLVVW XG\LVWREHFRQGXFWHGDFFRUGLQJWR*RRG&OLQLFDO
3UDFWLFHJXLGHOLQHVDVDGRSWHGE\)'$DSSOLFDEOHJRYHUQPHQWUH JXODWLRQVDQG,QVWLWXWLRQDOUHVHDUFKSROLFLHV
DQGSURFHGXUHV
 %DFNJURXQG

5HFHQWVPDOOVWXGLHVLQKXPDQVKDYHVKRZQWKDWLQWUDQDVDOR[\WR FLQUHGXFHVDSSHWLWHFDORULFLQWDNHERG\PDVV
LQGH[%0,DQGZDLVWFLUFXPIHUHQFH:&ZKLOHVLPXOWDQHRXVO\ LPSURYLQJSK\VLRORJLFSDUDPHWHUVVXFKDVIDW
DQGFDUERK\GUDWHXWLOL]DWLRQUHVSLUDWRU\TXRWLHQWDQGWRWDOF KROHVWHURO,QDVWXG\RI\RXQJPLGGOHDJHG
\HDUVROGPHQDQGDFURVVDVSHFWUXPRIZHLJKWVQRUP DOZHLJKWDQGRYHUZHLJKWREHVHDRQH
WLPHLQWUDQDVDOGRVHRILQWHUQDWLRQDOXQLW,8R[\WRFLQUHV XOWHGLQUHGXFHGWRWDOFDORULFLQWDNHDQGUHGXFHGIDW
LQWDNHDWDVXEVHTXHQWPHDO7KLVRQHWLPHGRVHRIR[\WRFLQDOVRUHVXOWHGLQUHGXFHGFKROH F\VWRNLQLQDQ
DQRUH[LJHQLFKRUPRQHIDVWLQJLQVXOLQDQGKRPHRVWDWLFPRGHODV VHVVPHQWRILQVXOLQUHVLVWDQFH+20$,5
$QRWKHUORQJHUWHUPZHHNVWXG\RI,8LQWUDQDVDOR[\WRFLQ IRXUWLPHVGDLO\LQ\RXQJPLGGOHDJHGDGXOWV
ZRPHQPHDQDJH\HDUVUHVXOWHGLQUHGXFHGERG\ZHLJKW %0,:&DQGWRWDOFKROHVWHURO

2[\WRFLQLVDQLQHDPLQRDFLGSRO\SHSWLGHSURGXFHGE\WKHVXSUD RSWLFDQGSDUDYHQWULFXODUK\SRWKDODPLFQXFOHL
DQGUHOHDVHGLQWRWKHFLUFXODWLRQYLDWKHSRVWHULRUSLWXLWDU\J ODQG2[\WRFLQLQGXFHVXWHULQHFRQWUDFWLRQVGXULQJ
GHOLYHU\DQGSURPRWHVODFWDWLRQLQZRPHQKRZHYHUR[\WRFLQFRQ WLQXHVWREHSURGXFHGDQGUHOHDVHGLQWRWKH
FLUFXODWLRQLQPHQDQGQRQSUHJQDQWZRPHQDQGLWVSODVPDFRQFHQ WUDWLRQGHFUHDVHVZLWKDJH7KHSK\VLRORJLF
UHOHYDQFHRIR[\WRFLQLQPHQDQGQRQSUHJQDQWZRPHQLVQRWFOHD UDVR[\WRFLQDGPLQLVWUDWLRQGRHVQRWLQGXFH
XWHULQHFRQWU DFWLRQVRUODFWDWLRQLQWKHVHLQVWDQFHV,QWKHEUDLQR[\WRFLQ LVWKRXJKWWRSOD\DUROHLQDVSHFWVRI
VRFLDOFRJQLWLRQDQGIRVWHULQJSURVRFLDOEHKDYLRUV&RQVHTXHQWO \R[\WRFLQDGPLQLVWUDWLRQLVEHLQJHYDOXDWHGIRU
WKHWUHDWPHQWRIDYDULHW\RIPHQWDOGLVRUGHUV
LQFOXGLQJ DXWLVP GHSUHVVLRQ DQG DQ[LHW\
2[\WRFLQUHJXODWHVIHHGLQJDQGPHWDEROLVPDW
PXOWLSOHVLWHVDQGWKURXJKPXOWLSOHPHFKDQLVPV
LQYROYLQJ ERWK FHQWUDO DQG SHULSKHUDO
PHFKDQLVPV ,W KDV UHFHQWO\ EHHQ
GHPRQVWUDWHG WKDW R[\WRFLQ DOVR VXSSUHVVHVDSSHWLWHLQERWKURGHQWV
DQGKXPDQV7KHVH
HIIHFWVDUHOLNHO\PHGLDWHGE\R[\WRFLQUHFHSWRUV
WKDW DUH H[SUHVVHG RQ JDVWULF YDJDO QHUYH
HQGLQJV DQG WKURXJKRXW WKH JDVWURLQWHVWLQDO
WUDFW ,QWUDQDVDO R[\WRFLQ LV VDIH DQG ZHOO
WROHUDWHG
 6LJQLILFDQFH
:LWKDJLQJWKHFDSDFLW\RIKXPDQWLVVXHVWRPDLQWDLQKRPHRVWDV LVDQGUHJHQHUDWHJUDGXDOO\GHFOLQHVDQG
HYHQWXDOO\IDLOVOHDGLQJWRGHJHQHUDWLYHDJHUHODWHGGLVHDVHV DQGJHULDWULFV\QGURPHV5HGXFWLRQLQPXVFOH
PDVVLQKXPDQVEHJLQVLQWKHWKLUGGHFDGHRIOLIHUHVXOWLQJLQ DSURJUHVVLYHGHFUHDVHLQVWUHQJWK0XVFOHDJLQJ
LVFKDUDFWHUL]HGE\DGHILFLHQF\LQPXVFOHUHJHQHUDWLRQDIWHUL QMXU\DQGE\PXVFOHDWURSK\OHDGLQJWRDOWHUHG
PXVFOHIXQFWLRQ7KHOLPLWLQJVWHSLQPXVFOHUHJHQHUDWLRQDSSHD UVWREHUHGXFHGDFWLYDWLRQRIWKHPXVFOHVWHP
FHOOVZLWKDJH7RUHJHQHUDWHPXVFOHWKHVHVWHPFHOOVEUHDNTXLHVFHQFHDQGS UROLIHUDWHWRIRUPQHZP\RILEHUV
6WHPFHOOVIURPDJHGPXVFOHKDYHWKHSRWHQWLDOWRUHSDLUGDPDJH GPXVFOHEXWDUHUHYHUVLEO\LQKLELWHGIURPGRLQJ
VRE\WKHHIIHFWVRIDJLQJ,QWH UHVWLQJO\DJHGPXVFOHVWHPFHO OVFDQEHUHVFXHGIRUWLVVXHUHSDLUE\DQXPEHURI
H[SHULPHQWDOPHWKRGVLQFOXGLQJR[\WRFLQH[SRVXUH


OXY -SAR-001   Page 3 
Version: 2.5 
0008_Protocol v2.5, 08- 03-18, AMD.docx  
CONFIDENTIAL  
Revised  version: v2.5 08- 03-18 1.4. Preliminary Data 
Recent work in mice showed that short -term systemic oxytocin delivery restores muscle regeneration in old mice 
by improving aged muscle stem cell function 4. This work also demonstrated that oxytocin acts directly on muscle 
stem cells (in vitro and in vivo) and that the pro- myogenic effects of oxytocin are mediated by MAPK/ERK 
signaling. The effect of oxytocin on skeletal muscle in humans has not yet been studied to our knowledge.     
1.5. Investigational Agent  
Intranasal oxytocin was marketed in the U.S. beginning in 1957 and used in the 1960â€™s in the postpartum period 
for milk let -down. It was taken off the market in 1995 in the U.S., but it is still available in Europe. There are 
several clinical trials now listed on clinicaltrials.gov studying the use of intranasal oxytocin for autism, dementia, 
and other psychological and developmental conditions.   
1.6. Dose Rationale and Risk/Benefits  
With assistance from the College of Pharmacy of University of Texas at Austin, we performed a literature review of the safety and side effect profile of intranasal oxytocin. To summarize, the studies reviewed that studied 
lactation did not have any significant adverse events or complications related to the use of intranasal oxytocin. 
The side effects noted with intranasal oxytocin were rare instances of headache, nausea, and allergic dermatiti s 
(between 1/1000 and 1/10,000 occurrences, and occasional abnormal uterine contractions (between 1/100 and 
1/1000 occurrences). In our study we expect fewer uterine contraction occurrences since none of the women 
enrolled will be postpartum and all will be post -menopausal. In studies that examined the use of intranasal 
oxytocin for conditions other than lactation, a recent article on this subject was also recently published 22. This 
article reviewed 38 trials and 3 case reports of both men and women. Mild adverse events were reported by 279 
out of 1529 subjects and consisted of light headedness, vertigo, drowsiness, sleepiness, dry mouth, nasal 
irritation, runny nose, abdominal pain, anxiety, euphoria, increased energy, relaxation, calm sensation, and 
headache.  
 
In this study we propose to use intranasal oxytocin to examine its physiologic and metabolic effects. We propose 
to use the same dose as recently reported by Zhang et al. 2.  In this recently conducted study, 24 subjects were 
randomized to intranasal oxytocin (24 IU QID) or placebo for a period of 8 weeks.  They demonstrated that there was no cardiovascular, hepatic or renal dysfunction related to the use of intranasal oxytocin. In fact, they noted 
improved hepatic function in the oxytocin group.  Ba
sed on the review of the literature and recent published 
studies indicating the safe use of intranasal oxytocin, we feel that intranasal oxytocin can be safely administered 
in a research study to examine its physiologic effects such as we propose.  
 
2. Study Objective  
a) To assess the effect of intranasal oxytocin administration on body weight, adiposity, muscle mass, and 
glucose tolerance in older adults.  
b) To assess the effect of intranasal oxytocin on physical function and physiologic parameters of insulin 
signaling, inflammation, and muscle regeneration in older adults.  
 
3. Study Design  
3.1. Subject s 
Population: 3 6 obese (BMI 30.0- 43.0 kg/m2) sarcopenic (see below)  subjects aged â‰¥60 years will be 
randomized to either intra- nasal oxytocin or placebo (saline) for 8 weeks.  Oxytocin (Syntocinon;  Novartis -
Switzerland  via  
OXY -SAR-001   Page 4 
Version: 2.5 
0008_Protocol v2.5, 08- 03-18, AMD.docx  
CONFIDENTIAL  
Revised  version: v2.5 08- 03-18   
Victoria Apotheke ZÃ¼ rich) will be dosed at 24 IU four times a day (before each meal and at bedtim e)2. 
Additional inclusion criteria (as shown 
in Table 1), are stable body weight, 
sedentary lifestyle (within the last 6 months), and sarcopenic obesity.  
 Sarcopenic obesity is defined using a 
modified consensus criteria of gait 
speed <1 meter/second
 12. Exclusion 
criteria are shown in Table 1.  Muscle mass will be measured as an outcome variable, however, it will not be used as 
a basis for inclusion.  
 
3.2. General Design  
 
Randomized, placebo controlled Phase 
II pilot study to be conducted at 3 
clinical sites: UTHealth San Antonio, 
UTHealth in Houston, and UTMB in 
Galveston.  
 
3.3. Study Endpoints  
 
Primary outcomes : Change in weight, adiposity,  
muscle mass, and physical function (gait speed, strength, SPPB) . This is a pilot study which will examine 
change in these outcomes prior to and after treatment.  
 
Secondary outcomes:  Change in glucose 
tolerance as measured by OGTT, measures of 
systemic inflammation ( TNF-Î±, C-reactive protein, 
IL-6, adiponectin), muscle inflammation (IL -1Î², IL -6, 
MCP -1, TNF -Î± mRNA), and muscle stem cell 
number and proliferative capacity. This is a pilot 
study which will examine change in these outcomes 
prior to and after treatment.  
 
3.4. Potential  Risks to Subject Safety  
Drug Administration.  
 
Rare : (observed in <1% of subjects)  
â€¢ Nausea 
â€¢ Allergic dermatitis  
â€¢ Occasional abnormal uterine contractions (unlikely in post -menopausal subjects)  
â€¢ Hyponatremia and or fluid imbalance  
 
Mild: (observed in 10 -20% of subjects)  able 1. Inclusion and exclusion criteria  
Inclusion Criteria  
Age â‰¥60 years  
BMI 30.0 -43.0 kg/m2 with stable body weight (Â±2%) in past 3 months  
Sedentary (â‰¤2 strenuous exercise/week)  
Gait speed < 1 meter/second  
Exclusion Criteria  
Diabetes  with HbA1c â‰¥  6.5 and/or taking medications known to effect glucose 
homeostasis , Significant heart disease (history of MI within the last year or New 
York Heart Classification grade III -IV) Poorly controlled hypertension (SBP >170 or 
DBP >95 mmHg), Anemia, Renal Disease  (as specified in Section 4 below) , or Liver 
Disease  
Use of systemic steroids/androgens or anticoagulants  
Active/unstable inflammatory, thyroid, autoimmune, gastrointestinal (GI), 
hematologic or neoplastic disorders  (Exclude subjects with clinical lab values 
outside the normal range  (other than as specified above) ) 
Cognit ive impairment (Mini -Cog <3), unstable mental illness or GDS >  7, 
substance abuse, or history of eating disorder  
Table 2. Outcome variables  
Primary Outcome  Secondary Outcome  
Adiposity (BMI, DEXA)  Glucose tolerance (OGTT)  
Muscle mass (DEXA, MRI, 
muscle fiber CSA)  Systemic and muscle 
inflammation  
Physical function (gait speed, 
muscle strength, balance)  Muscle stem cell number and 
proliferative capacity  
OXY -SAR-001   Page 5 
Version: 2.5 
0008_Protocol v2.5, 08- 03-18, AMD.docx  
CONFIDENTIAL  
Revised  version: v2.5 08- 03-18 â€¢ Light -headedness  
â€¢ Vertigo  
â€¢ Drowsiness  
â€¢ Sleepiness  
â€¢ Dry mouth  
â€¢ Nasal irritation  
â€¢ Runny nose 
â€¢ Abdominal pain 
â€¢ Anxiety  
â€¢ Euphoria 
â€¢ Increased energy  
â€¢ Relaxation  
â€¢ Calm sensation 
â€¢ Headache 
Blood withdrawal.   
All studies involve the withdrawal of blood. Any subject who has donated blood in the previous two months 
will not be studied. The subjects will be instructed not to donate blood for two months after the study.  Any 
subject with a hematocrit of < 34% will not be studied.  Blood will be collected for safety and for research 
purposes at screening and study visits.  Upon subject -reported history of any condition (known or suspected) 
that would be exclusionary , investigator may choose to order appropriate additional clinical labs to ensure 
eligibility.  
IV lines.   
Catheters will be placed in an antecubital vein or a hand vein for the OGTT.  Local hematomas occur in 
about 1% of catheterizations.  Infection is possible (<1%), but we have not experienced this  complication.   
Muscle biopsy.   
At the time of biopsy, subjects may feel pain, discomfort, or pressure (variably described by different 
subjects) for about 5- 10 seconds.  Pain or discomfort ceases as soon as the cannula is withdrawn.  Local 
hematomas occ ur in <2% of subjects.  One patient experienced a moderately painful hematoma that 
resolved within 2 weeks (0.1%).  About 1 in 50 subjects report non -clinically evident numbness or altered 
sensation at the biopsy site, which is transient.  
 
There is the possibility that a future biopsy may not be done at the discretion of the PI in case the subject 
did not tolerate well a prior biopsy.  
Radiation exposure.  
Subjects will be exposed to a small amount of radioactivity during DEXA.  
 
4. Subject Selection and Withdrawal  
4.1. Inclusion Criteria  
â€¢ Both genders.  
â€¢ Age â‰¥ 60 years.  
â€¢ All ethnic groups.  
â€¢ BMI 30.0-43.0 kg/m2 with stable body weight ( Â±2%) in past 3 months.  
â€¢ Sedentary ( â‰¤2 sessions of strenuous exercise/w eek) 
OXY -SAR-001   Page 6 
Version: 2.5 
0008_Protocol v2.5, 08- 03-18, AMD.docx  
CONFIDENTIAL  
Revised  version: v2.5 08- 03-18 â€¢ Gait speed < 1 meter/second  
â€¢ Labs: HCT â‰¥34%,  GFR â‰¥ 30 mL/min, liver enzymes  (AST < 2 x upper limit of normal, ALT < 2 x upper 
limit of normal, alkaline phosphatase < 2 X upper limit of normal), normal electrolytes,  urinalysis with < 
5 red blood cells (RBCs) and < 5 white blood cells (WBCs) , and normal PT and PTT. If additional labs 
are drawn to ensure eligibility, inclusion requires lab results fall within the normal range per local lab.  
Note: Some sites may draw additional clinical labs per local standard operating procedure, which are not 
collected as research dat a for this study.  
 
 
4.2. Exclusion Criteria  
â€¢ Diabetes  with HbA1c â‰¥ 6.5 and/or taking medications known to effect glucose homeostasis   
â€¢ Significant heart disease (history of MI within the last year or New York Heart Classification grade III -IV) 
â€¢ Poorly controlled hypertension (SBP >170 or DBP >95 mmHg)  
â€¢ Anemia (HCT <34%) 
â€¢ Renal Disease ( GFR < 30 mL/min) , abnormal serum sodium levels, urinalysis  with â‰¥ 5 RBCs or â‰¥ 5 
WBCs , or physical exam findings indicative of fluid imbalance; individuals with underlying disorder of  
sodium/water balance, such as SIADH, diabetes insipidus, or psychogenic polydipsia  
â€¢ Liver Disease or abnormal liver enzymes (AST > 2 x upper limit of normal, ALT > 2 x upper limit of 
normal, alkaline phosphatase > 2 X upper limit of normal)  
â€¢ Use of systemic  steroids or androgens  
â€¢ Individuals with underlying seizure disorder or underlying neurologic disorder that increases seizure risk  
â€¢ Current treatment with anticoagulants ( i.e. warfarin). Aspirin (up to 325 mg) and clopidogrel will be 
permitted if these can be held for seven days prior to the biopsies.  
â€¢ Active/unstable conditions: inflammatory, thyroid, autoimmune, gastrointestinal (GI), hematologic, or 
neoplastic disorders.  Exclude subjects with clinical lab values outside the normal range (other than as 
specified above).  
â€¢ Cognitive impairment ( Mini-Cog <3 ) 
â€¢ Unstable mental illness  (GDS > 7) 
â€¢ Substance abuse  
â€¢ History of eating disorder  
â€¢ Subject is considered unsuitable for the study in the opinion of the investigator for any other reason  
4.3. Subject Recruitment and Screening  
Subjects will be recruited through the institutional volunteer registries and advertisement (newspaper, fl yers, 
etc.). All study visits will be performed in the Clinical Research Centers (CRCs) of UTHealth San Antonio, UHS , 
UTMB and UTHealth- Houston. At some sites, subjects will call-in to an advertised number and will be pre-
screened using an institutionally -approved process.  Callers then provide permission for a research team 
member to  follow up with phone screening using an IRB -approved form (sample contained in Attachment D 
section) and staff will schedule the screening visit if the potential subject agrees  If potentially eligible following 
the telephone screening process , an in -person screening visit will be conducted.   
 
Screening evaluation will follow informed consent at Visit 1 and will include: medical history, physical 
examination (including anthropometric measurements), Mini -Cog, and screening blood tests (complete blood 
count, chemistry, lipid profile, hemoglobin A1c, coagulation tests , urinalysis) . 
 
 
OXY -SAR-001   Page 7 
Version: 2.5 
0008_Protocol v2.5, 08- 03-18, AMD.docx  
CONFIDENTIAL  
Revised  version: v2.5 08- 03-18  
 
4.4. Early Withdrawal of Subjects  
4.4.1. When and How to Withdraw Subjects  
Subjects have the right to withdraw fully or partially from the study at any time and for any reason without 
prejudice to his or her future medical care by the physician or at the institution.  
 Withdrawal of full consent for a study means that the subject does not wish to receive further investigational treatment and does not wish to or is unable to continue further study participation including any follow -up in 
person, by phone, through third parties including relatives or friends, via discussion with other treating physicians, and by use of medical records; subject data up to withdrawal of full consent will be included in the analysis of the study. Any subject may withdraw full consent to participate in the study at any time during the study. The Investigator or sub- investigator will discuss with the subject appropriate procedures for withdrawal 
from the study.  
 
Final Study Visit for Withdraw n Subjects  
At the tim e of receiving notification of intended withdrawal, researchers will ask subject to complete a final 
visit. The informed consent document advises subjects to discuss withdrawal decision with the principal  
investigator.  This visit includes  a repeat  history  and physical  examination,
 weight,  functional testing, 
Bioimpedance (UTMB site only) , DEXA,  questionnaires, and laboratory  tests (safety labs, inflammatory 
markers). Subjects may choose to complete  all or part of the final study visit.  
 4.4.2. Data Collection and Follow -up for Withdrawn Subjects 
If subjects are withdrawn prematurely from the study, appropriately designated research staff will make efforts 
to collect at least survival data throughout the protocol defined follow -up period for that subj ect.  
 Investigator will consult with Study Statistician with regard to any incomplete data set as compared to the full data set that fully supports the analysis.  If a subject withdraws consent to participate in the study, attempts will be made to obtain permission to record survival data up to the protocol -described end of subject follow -up period.  
 Investigator and designated research staff make it a high priority to obtain survival data on all subjects lost to follow up. Lost to follow up will be defined as a subject missing 2 or more consecutive visits, not answering or responding to 3 follow up phone calls to subject or emergency contacts, or returned receipt of 1 certified letter.  
5. Study Drug  
5.1. Description  
See Attachment D. Victoria Apotheke Zurich: Syntocinon, Drug information 
5.2. Treatment Regimen  
Subjects  are instructed to administer 3 sprays per nostril (24 IU) 4 times a day  for 8 weeks (56 days) . 
Method for Assigning Subjects to Treatment Groups  
The randomization key will be designed by a biostatisti cian or sponsorâ€™s designee not directly engaged in the 
research and key will be provided to the research pharmacy for coding study drug. After the key is created, t he 
research  pharmacy will keep the randomization key in case unblinding is necessary at any point during the 
OXY -SAR-001   Page 8 
Version: 2.5 
0008_Protocol v2.5, 08- 03-18, AMD.docx  
CONFIDENTIAL  
Revised  version: v2.5 08- 03-18 study.  
 
Subject ID numbers will be generated in REDCap based on the data management design. The Study 
Coordinator at each site stores the Enrollment key, which is kept in a locked cabinet  or on a secure server with 
limited access .  
 Study staff maintains data records , and specimens , in a de- identified m anner  using only the unique Subject 
ID/Randomization number.  Only the secure source documents may contain subject identifiers (name, DOB, 
SSN, etc.)  
5.3. Preparation and Administration of Study Drug 
Intranasal Administration Protocol.  
To prime a new bottle:  
â€¢ Hold the bottle upright and away from you, then pump it several times until you see a faint spray.  
â€¢ Do not  prime the pump again before each daily use.  
 
To use the nose spray:  
â€¢ Before using the spray, blow your nose gently to clear the nostrils.  
â€¢ Keeping your head in an upright position, carefully place the nozzle into one nostril, aiming straight back 
toward the base of the skull. Do not aim the nozzle straight up toward the top of the head.  
â€¢ Press the pump toward the bottle and spray as directed.  
â€¢ Do not inhale while spraying. Breathe or sniff gently through the nose after spraying and do not blow 
nose again f or at least 30 minutes.  
â€¢ To keep the nosepiece clean, wipe it with a clean tissue and replace the dust cap after use.  
 
Subject Compliance Monitoring  
A drug diary will be provided to all subjects at the time of drug dispensing  at Visit 3 (or Visit 4 if opti onal MRI is 
completed). Subjects  will be instructed to log their use of the study drug daily and bring the drug diary to each 
visit. 
5.4. Prior and Concomitant Therapy  
Exclusionary medications:  
Drugs that affect glucose homeostasis, systemic corticosteroids, androgens.  
Treatment with anticoagulants (warfarin). Aspirin (up to 325 mg) and clopidogrel will be permitted if these can 
be held for seven days prior to the biopsies. 
5.5. Packaging    
 
Nature and Contents of the Container  
Victoria Apotheke Zurich will supply  blinded product and placebo, package for refrigerated shipping, and manage 
customs and importation documents.  
5.6. Receipt, Storage and Handling of Study Drug 
Local site Research Pharmacy  will be responsible fo r receipt, inventory, storage, and destruction of Study Drug.  
OXY -SAR-001   Page 9 
Version: 2.5 
0008_Protocol v2.5, 08- 03-18, AMD.docx  
CONFIDENTIAL  
Revised  version: v2.5 08- 03-18 Receipt of Drug Supplies 
Any damaged or unusable study drug in a given shipment will be documented by the receiving Pharmacy.  The 
Research Pharmacist will notify the IND Sponsor  of any damaged study drug.  
 
Special instructions upon receipt  
Open package, review and compare to shipping documents, log inventory counts and refrigerate.  
Storage  
Nasal spray : Store in a refrigerator (2 â€“8Â°C or 35.6Â°Fâ€“ 46.4F).  
Shelf life : After opening the bottle, store t he nasal spray at room temperature (15â€“ 25Â°C) and use within 1 month.  
Dispensing of Study Drug 
Designated staff from the site Research Pharmacy maintains  the Drug Accountability Logs to track how, when 
and to whom the investigational drug was prescribed, dispensed and assigned to subjects. Study clinical staff 
will keep drug administration records regarding drug that is  damaged  or wasted.   
 
Routine study drug administration and reconciliation will be performed based on clinical site  policy and standard 
operating procedures . 
Return or Destruction of Study Drug 
The procedures for final reconciliation of the siteâ€™s drug supply at the end of the study will be in accordance with 
local site  Pharmac y standard operating procedures. There are no special precautions  cited for disposal of 
Intranasal Oxytocin. 
 
6. Study Procedures  
Study  visits.  All studies  will be performed  in the Clinical Research Center at the designated site(s). 
6.1. Visit 1  (Consent , Screening  for Eligibility , and Baseline Testing  â€“ Day 0) 
Subjects present in fasting state to the site CRC at appointed time for informed consent processing, medical 
history and physical exam to assess inclusion and exclusion criteria, including measurements of weight , gait 
speed, waist circumference, hematology,  coagulation studies, chemistry with liver function, lipid panel , urinalysis,  
and serum and urine osmolality . A 2-hour OGTT will be performed to assess glucose tolerance. . Screening mental 
status assessment s (Mini -Cog and depression scale) will be performed  to ensure valid consenting process . If 
subjects meet initial eligibility criteria based on walking speed and history & physical examination.  Individuals 
meeting eligibility will proceed to a 2- hour OGTT . During the 2- hour OGTT,  baseline testing will be performed, 
including labs, food recall and appetite assessments and psychometrics. After the 2 -hour OGTT, the participant 
will be given a meal or substantial snack (per local clinical research unit) and continue with the functional testing.  
A scre ening window of 30 days is allowed so that all laboratory and test results can be returned and reviewed.  
Estimated length of  this visit is 6 hours.  
â€¢ Vital signs will be assessed for blood pressure, heart rate, respiratory rate and temperature  
â€¢ Walking speed will be assessed at usual speed over a 15-foot course  
â€¢ Waist circumference will be measured in inches and converted to centimeters.  
â€¢ Weight  in pounds will be measured or calculated in kilograms and used in BMI calculation. 
â€¢ History & physical examination, targeted to the inclusion & exclusion criteria will be performed to 
determine study eligibility.   
OXY -SAR-001   Page 10 
Version: 2.5 
0008_Protocol v2.5, 08- 03-18, AMD.docx  
CONFIDENTIAL  
Revised  version: v2.5 08- 03-18 â€¢ Laboratory tests : CBC, CMP with liver function, Hemoglobin A1c, coagulation test (PT/INR, PTT), 
urinalysis, serum osmolality, urine osmolality, lipid  panel . Order additional labs, if necessary, based on 
pertinent medical history.  
â€¢ Psychometrics : Mini -Cog scoring < 3 will not be studied; Geriatric Depression Scale (GDS)  scoring > 7 
will not be studied and warrants follow up assessment with mental health professional  
â€¢ Electrocardiogram  (ECG) : ECG with definitive evidence of prior myocardial infarction will not be studied  
â€¢ 2-hour OGTT : Baseline (fasting) samples for determination of glucose and insulin concentrations will be 
drawn at -30, and -15 minutes (the se basal values are averaged). At time zero, each subject will ingest 
75 g of glucose. Glucose and insulin are determined every 30 minutes for 2 hours  following glucose 
ingestion. The Matsuda index of insulin sensitivity will be calculated from the OGTT results, as described 
13.   
â€¢ Food recall and appetite assessments : A 24 -hour food recall, 3-day food diary , and appetite will be 
assessed using standardized questionnaires14, 15. 
â€¢ Psychometrics : The Montreal Cognitive Assessment (MOCA) and The Centers for Epidemiologic Studies 
Depression Scale (CES- D) will be administered for baseline measurement.  
â€¢ Functional Testing : Timed Up and Go (TUG) and Short Performance Physical Performance Battery 
(SPPB, modified) will be measured using standardized methods 23, 24. Grip strength will be assessed 
using handheld digital dynamometer. 
 
6.2. Visit 2: Optional MRI  (within 7 days after V1)  
MRI (optional) : Image of the abdomen  and dominant lower extremity  will be done if funding is available to examine 
the effect of oxytocin on abdominal visceral fat and  thigh muscle volume as described 25. If participant has a 
pacemaker or any other reason that would preclude obtaining an MRI, this procedure can be omitted at the 
discretion of the PI.  
 
6.3. Visit 3  â€“ Physiological measures and Rando mization  (within 7-14 days after V 2) 
 
Subjects present to the site CRC in fasting  state  to assess body composition, bioimpedance, calorimetry, 
muscle biopsy, and systemic inflammation.  An intravenous (IV) line is placed for access during muscle biopsy.  
â€¢ Vitals signs, weight and BMI  
â€¢ DEXA : Whole body dual -energy X -ray absorptiometry is performed to measure lean and fat body mass  
â€¢ Bioimpedance: Measures weight, body fat percentage, and body mass index (BMI). The BF- 350 is an 
FDA-cleared body composition monitor is an affordable solution for mainstream healthcare and fitness 
providers.  Bioimpedance will be performed at UTMB Galveston site only.  
â€¢ Calorimetry : Indirect calorimetry is performed in fasting state at rest for 30 minutes. Calorimetry will not 
be performed at UT Houston due to unavailability of required equipment. Since this is not a major outcome 
of the study, this does not significantly affect the scientific integrity of the study.  
â€¢ Muscle Biopsy : Vastus lateralis muscle needle biopsy will be performed to assess muscle fiber type, 
satellite cells, and inflammatory markers.  
â€¢ Laboratory and blood draw : Systemic inflammatory markers (see Analyses)  
OXY -SAR-001   Page 11 
Version: 2.5 
0008_Protocol v2.5, 08- 03-18, AMD.docx  
CONFIDENTIAL  
Revised  version: v2.5 08- 03-18 â€¢ Adverse event review questionnaire will be completed.  
 
Analyses.   
Muscle:   
A biopsy of the vastus lateralis muscle will be performed as described using aseptic technique 17. The following 
measurements will be performed:  
â€¢ Muscle fiber cross sectional area (CSA) 18 
â€¢ Satellite (stem) cell number and proliferative capacity 19, 20 
â€¢ Inflammatory genes / proteins.  Measurements of NF ÎºB and MAPK signaling, two key mediators of the 
inflammation state, will be conducted as described 21. We will also assess cellular inflammation by 
measuring the levels of the mRNA transcri pts for IL -1Î², IL -6, MCP -1, and TNFÎ± mRNA in skeletal muscle 
before and after oxytocin treatment 21.   
Blood/plasma:  
â€¢ Systemic inflammation - measuring plasma concentration of TNF- Î±, C -reactive protein, IL -6, and 
adiponectin, using commercially available ELISA kits.  
 
Randomization.  Subject will be randomized to study drug or placebo and dispensing occurs at the end of V3.  
 
6.4. Visit 4. Safety Labs (+1 week since start of study drug, within Â±3-day window) and drug tolerability  
Subjects present in fasting state to the site CRC to assess:  
â€¢ Vital signs, weight, BMI, waist circumference  
â€¢ Safety labs : Chemistry (including serum sodium), liver function, urine  osmolality and serum osmolality  
â€¢ Food recall: repeat 24- hour food recall, 3 -day food diary and appetite assessments (same as Visit 1) 
â€¢ Drug tolerability : subjects will be assessed for drug tolerability, including any side effects or adverse effects. 
Special attention will be made for signs and symptoms suggestive of hyponatremia including lethargy, 
muscle spasms, seizures, confusion/delirium, nausea and vomiting 
 
6.5. Visit 5 Safety Labs (+4 week s of drug administration, within Â±7-day window)  and drug tolerability  
Subjects present in fasting state to the site CRC to assess:  
â€¢ Vital signs, w eight, BMI, waist circumference  
â€¢ Drug compliance and tolerability , AE review  
â€¢ Psychometrics : repeat MOCA and CES-D 
â€¢ Food recall:  same as Visit 1 
â€¢ Safety labs: chemistry  with liver function, urine osmolality and serum osmolality  
 
6.6. Visit 6;  Post treatment measurements (6-7.5 weeks on treatment )  
Subjects present in fasting state to the site CRC to assess:  
â€¢ Vital signs, weight, BMI, waist circumference  
â€¢ Laboratory : CBC, chemistry with liver function, lipid panel, urine and serum osmolality, hemoglobin A1c, 
coagulation tests (PT/INR, PTT)  
â€¢ Functional testing: Gait speed, grip strength, modified SPPB, TUG  
â€¢ Food recall : same as Visit 1 
OXY -SAR-001   Page 12 
Version: 2.5 
0008_Protocol v2.5, 08- 03-18, AMD.docx  
CONFIDENTIAL  
Revised  version: v2.5 08- 03-18 â€¢ 2-hour OGTT  
â€¢ Drug compliance and tolerability, AE review   
6.7. Visit 7: Optional MRI (if done a t V2) â€“ (7-7.5 weeks on treatment)   
MRI (optional) : Image of the abdomen and dominant lower extremity  will be done if completed at Visit 2 . If 
participant has a pacemaker or any other reason that would preclude obtaining an MRI, this procedure can be 
omitted at the discretion of the PI.  
6.8. Visit 8 : Post treatment measurements (7.5-8 weeks of treatment ) 
Subjects present in fasting state to the site CRC to assess:  
â€¢ Vitals signs, weight, BMI, waist  circumference  
â€¢ MOCA, CES -D 
â€¢ DEXA body composition, Bioimpedance (UTMB Galveston only)  and Calorimetry  
â€¢ Muscle biopsy  (satellite cell, fiber type, fat infiltration, inflammation, gene expression)  
â€¢ Blood draw : Systemic inflammation 
â€¢ Drug tolerability, compliance, and AE review  
 
 
See Summary of Visits Table on next page.  
 
    
 
     
 
     
 
    
 
     
 
    
Summary of Visits Table  
 
OXY -SAR-001   Page 13 
Version: 2.5 
0008_Protocol v2.5, 08- 03-18, AMD.docx  
CONFIDENTIAL  
Revised  version: v2.5 08- 03-18   Visit 1  Visit 2  Visit 3  Visit 4  Visit 5  Visit 6  Visit 7  Visit 8  
  Screen  
Day 0 
(fasting)   MRI 
+ 7d  V2     
+7-14d 
(fasting)  1 week on 
treatment  
(fasting)  4 weeks 
on  
treatment  
(fasting)  6-7.5 
weeks on 
treatment  
(fasting)  MRI  
7-7.5 
weeks on 
treatment            7.5-8 
weeks on 
treatment  
(fasting)  
Medical history and 
physical examination, 
ECG  X 
              
Vital signs, Weight, BMI  X   X  X   X X  
X 
Waist circumference  X   X X X  X 
Mini-Cog X               
Montreal Cognitive 
Assessment (MOCA)  X    X   X 
Geriatric depression scale 
(GDS)  X        
Centers for Epidemiologic 
Studies Depression Scale 
(CES -D) X    X   X 
Gait speed, 15 -foot course  X          X    
Electrocardiogram  X        
**CBC, HgbA1c, and 
Coagulation testing 
(PT/INR, PTT)  X          X    
**Chemistry with liver    
function, serum osmolality  
(other safety labs if 
clinically indicated by 
history)  X      X X X    
**Lipid Panel  X     X   
Urinalysis  X               
Urine osmolality  X      X X  X    
OGTT, 2 -hour X     X   
Body composition (DEXA)     X     X 
Bioimpedance  (UTMB 
only)     X     X 
Calorimetry     X     X 
Randomization *   X      
Body composition    (MRI) 
- optional     X         X  
Functional tests: mSPPB, 
TUG, grip strength  X     X   
24-hour food recall, 3-day 
food diary, appetite  X   X X X   
Muscle biopsy    X     X 
Systemic inflammation    X     X 
Drug tolerability, 
compliance,AE review      AE 
review 
only  X  X X  X 
 
* After Visit 4 , participants may receive periodic phone calls by study staff between study visits to assess any 
symptoms and encourage adherence to study drug.  
** Any marginally abnormal lab findings may be repeated if clinically indicated to ensure initial  or continued 
eligibility.  
OXY -SAR-001   Page 14 
Version: 2.5 
0008_Protocol v2.5, 08- 03-18, AMD.docx  
CONFIDENTIAL  
Revised  version: v2.5 08- 03-18 7. Statistical Plan  
7.1. Sample Size Determination   
Our power and sample size estimation is based on findings from an 8- week study of intranasal oxytocin in 24 
adults , which found a greater reduction in body weight and BMI with oxytocin. Based on their findings, our 
proposed study  (12 completers each site for 36 completers total, 18 completers in each arm) is expected to 
have 96.4% power to detect the oxytocin effect  if the standard deviation (SD) associated with weight loss is 
6.0 kg in the oxytocin group and 1.5 kg in the control  group. For a more conservative estimate assuming a SD 
of 6.0 in both the oxytocin and control groups, our study would have 78.2% power. For both these power 
analyses, we assume type 1 error of P=0.05.  
 
7.2. Statistical Methods  
Analytical  Approach . 
Generalized linear mixed effects model will be used to evaluate the effect of oxytocin on the change of each continuous measure.  The effect of oxytocin will be assessed by whether the time by oxytocin interaction is 
significantly different from 0 with a 2- sided p- value<0.05. Normal transformed score of an outcome will be used 
in the analyses when appropriate.   
8. Safety and Adverse Events  
8.1. Definitions  
Adverse Event (AE)  
In general, AE is used very broadly and encompasses physical and psychological harms and i ncludes:   
 Any untoward or unfavorable medical occurrence in a human subject, including any abnormal sign (for 
example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with 
the subjectâ€™s participation in the research , whether or not it is considered related to the subjectâ€™s participation 
in the research.  
 
Intercurrent illnesses or injuries should be regarded as adverse events.  Abnormal results of diagnostic 
procedures are considered to be adverse events if the abnormality:  
â€¢ results in study withdrawal  
â€¢ is associated with a serious adverse event  
â€¢ is associated with clinical signs or symptoms  
â€¢ leads to additional treatment or to further diagnostic tests  
â€¢ is consider ed by the investigator to be of clinical significance  
 
Serious Adverse Event (SAE)  
Adverse events are classified as serious or non -serious.  A serious adverse event is any AE that:  
â€¢ results in death;  
â€¢ is life -threatening (places the subject at immediate risk of death from the event as it occurred);  
â€¢ results in inpatient hospitalization or prolongation of existing hospitalization;  
â€¢ results in a persistent or significant disability/incapacity;  
â€¢ results in a congenital anomaly/birth defect; or  
â€¢ based upon appropriate medical judgment, may jeopardize the subjectâ€™s health and may require medical 
or surgical intervention to prevent one of the other outcomes listed in this definition (examples of such 
OXY -SAR-001   Page 15 
Version: 2.5 
0008_Protocol v2.5, 08- 03-18, AMD.docx  
CONFIDENTIAL  
Revised  version: v2.5 08- 03-18 events include allergic bronchospasm requiring intensive treatment  in the emergency room or at home, 
blood dyscrasias or convulsions that do not result in inpatient hospitalization, or the development of drug 
dependency or drug abuse).  
 
Unanticipated Problems Involving Risk to Subjects or Others (UPIRSO)  
Any incident, experience, or outcome that meets all of the following criteria:  
â€¢ Unexpected  in nature, severity, or frequency  (i.e. not described in study -related documents such as the 
IRB-approved protocol or consent form, the investigators brochure, etc .) 
â€¢ Related or possibly related to participation in the research (i.e. possibly related means there is a 
reasonable possibility that the incident experience, or outcome may have been caused by the procedures involved in the research)  
â€¢ Suggests that the research places subjects or others at greater risk of harm  (including physical, 
psychological, economic, or social harm).  
 Adverse Event Reporting Period  
The study period during which adverse events must be reported is normally defined as the period from t he 
initiation of any study procedures to the end of the study treatment follow -up.  For this study, the study treatment 
follow -up is defined as 7 days following the last administration of study treatment.  
 Pre-existing Condition  
A preexisting condition is  one that is present at the start of the study.  A pre- existing condition should be recorded 
as an adverse event if the frequency, intensity, or the character of the condition worsens during the study period.  
 
General Physical Examination Findings  
At scree ning, any clinically significant abnormality should be recorded as a preexisting condition.  At the end of 
the study, any new clinically significant findings/abnormalities that meet the definition of an adverse event must 
also be recorded and documented as  an adverse event.  
 
Abnormal Laboratory Values  
A clinical laboratory abnormality should be documented as an adverse event if any one of the following  conditions 
is met:  
â€¢ The laboratory abnormality is not otherwise refuted by a repeat test  to confirm the abnormality  
â€¢ The abnormality suggests a disease and/or organ toxicity  
â€¢ The abnormality is of a degree that requires active management ; e.g. change of dose, discontinuation of 
the drug, more frequent follow -up assessments, further diagnostic investigation, etc . 
 
Hospitalization, Prolonged Hospitalization or Surgery  
Any adverse event that results in hospitalization or prolonged hospitalization should be documented and reported 
as a SAE unless specifically instructed otherwise in this protocol.  Any condition responsible for surgery should 
be documented as an AE if the condition meets the criteria for and adverse event. Neither the condition, 
hospitalization, prolonged hospitalization, nor surgery are reported as an AE in the following circumstances:  
â€¢ Hospitaliz ation or prolonged hospitalization for diagnostic or elective surgical procedures for a preexisting 
condition.  
â€¢ Surgery should not be reported as an outcome of an adverse event if the purpose of the surgery was 
elective or diagnostic and the outcome was uneventful.  
â€¢ Hospitalization or prolonged hospitalization required to allow efficacy measurement for the study.  
â€¢ Hospitalization or prolonged hospitalization for therapy of the target disease of the study, unless it is a worsening or increase in frequency of hospital admissions
 as judged by the clinical investigator.  
OXY -SAR-001   Page 16 
Version: 2.5 
0008_Protocol v2.5, 08- 03-18, AMD.docx  
CONFIDENTIAL  
Revised  version: v2.5 08- 03-18 8.2. Recording and Reporting of Adverse Events and Protocol Deviations  
At each contact with the subject, the investigator or study staff will seek information about adverse events by 
specific questioning and, if appropriate, by examination.  The principal investigator will review the safety and 
progress of this study on a continuing basis. Safety data will be reviewed at each study visit. Information on all 
adverse events will be recorded immediately in the source document, and also in the appropriate adverse event 
section of the case report form.  
 
â€¢ AEs will be tracked using the HSC IRB AE tracking form or data management tool (See Section 9.3) to 
be reviewed by Site Investigator weekly and IND Sponsor  monthly.  
 
â€¢ All AEs occurring during the study period will be recorded. The clinical course of each event will be followed until resolution, stabilization, or until it has been determined that the study treatment or participation is not the cause.   
 
â€¢ All adverse events will be summarized annually and submitted to the IRB.   
 
â€¢ Deviations  from the approved protocol (PDs) will be recorded in the site Protocol Deviation Log. When a 
deviation occurs s ite investigators or r esearch staff will notify the site IRB and the IND sponsor as 
appropriate per local policy and procedure. 
 
â€¢ The IND Sponsor records every PD in a study -wide log and review s within 48 hours of notification to 
determine if prompt r eporting  to IRB of record  is required .  
 
8.3. Recording and Reporting of Serious Adverse Events and Unanticipated Problems  
 
SAEs a nd UPIRSOs will be reported per governing IRB policy and procedure.  
â€¢ UPIRSOs  that are a result of study participation are reported to the IRB and the Medical S afety Officer 
within 24 hours. The report will include a description of the event, when and how it was reported, as well 
as any official chart records or documentation to corroborate the event or the reporting of the event. All 
adverse events will be graded as mi ld, moderate, or severe.   
â€¢ SAEs will also be submitted to the IRB and the safety officer within 24 hours.  
â€¢ SAEs that are still ongoing at the end of the study period will be followed up to determine the final outcome.  
Any SAE that occurs after the study period and is considered to be possibly related to the study treatment or study participation will be recorded and reported per Institutional  
policy and according to FDA 
requirements.  
 
Any action resulting in a temporary or permanent suspension of this study (e.g. local site IRB actions) will be 
reported to the IND Sponsor . 
Investigator reporting: notifying the IND sponsor  
Any study -related UPIRSO, and any type of SAE, must be reported to IND Sponsor  by telephone within 24 hours 
of the event.  To report such events, a Serious Adverse Event (SAE) form must be completed by the investigator and faxed to IND sponsor within 24 hours .  The investigator will keep a copy of this SAE form on file at the study 
site.   
 Report SAE /UPIRSOs by email or facsimile to: 
 
Sara E. Espinoza, MD  
Associate Professor, Department of Medicine  
OXY -SAR-001   Page 17 
Version: 2.5 
0008_Protocol v2.5, 08- 03-18, AMD.docx  
CONFIDENTIAL  
Revised  version: v2.5 08- 03-18 University of Texas Health Science Center at San Antonio  
Barshop Institute for Longevity and Aging Studies  
7703 Floyd Curl Dr ive 
Mail Co de 7886 
San Antonio, Texas 78229- 3900  
(210) 617- 5197  (phone) â€“ (210) 562 -6130 (fax)  
Email: espinozas2@uthscsa.edu  
 
Within the following 48 hours, the investigator must provide further information on the SAE or the UPIRSO in the 
form of a written narrative.  This should include a copy of the completed SAE form, and any other diagnostic 
information that will assist the understanding of the event.   
 
Reporting Process: Notifying the UTHSCSA IRB  
Adverse events not requiring immediate reporting may be tracked at each site on UTHSCSA Adverse Event 
Tracking Form  (Track both UPIRSO and Events and Problems Not Requiring Prompt Reporting) and will be 
collected in REDCap . For SAE and UPIRSO, use UTHSCSA  Prompt Reporting Form . 
Sponsor reporting: Notifying the FDA  
â€¢ Within 7 calendar days  
Any study event that is : 
â€“ associated with the use of the study drug 
â€“ unexpected,  
â€“ fatal or life -threatening, and  
 
â€¢ Within 15 calendar days 
Any study event that is:  
â€“ associated  with the use of the study drug,  
â€“ unexpected, and  
â€“ serious, but not fatal or life- threatening 
-or- 
â€“ previous adverse event that was not initially deemed reportable but is later found to fit the criteria for 
reporting (reporting within 15 calendar days from when  event was deemed reportable).  
Any finding from tests in laboratory animals that:  
â€“ suggest a significant risk for human subjects including reports of mutagenicity, teratogenicity, or 
carcinogenicity.  
 
Sponsor Reporting Process 
Serious adverse events may be submitted on FDA Form 3500A or  in a narrative format. The contact information 
for submitting IND safety reports is noted on the next page.  
 
Food and Drug Administration 
Center for Drug Evaluation and Research  
Division of Metabolism and Endocrinology Products  
5901- B Ammendale Road 
Belts ville, MD 20705- 1266 
Phone: (301) 796- 2290  
Fax: (301) 796- 9712  
8.4. Medical Monitoring  
The IND Sponsor  will review the safety and progress of this study on a monthly basis or when  needed if SAE 
OXY -SAR-001   Page 18 
Version: 2.5 
0008_Protocol v2.5, 08- 03-18, AMD.docx  
CONFIDENTIAL  
Revised  version: v2.5 08- 03-18 or SAE -UPIRSO occurs.  The Medical Safety Officer is Dean L. Kellogg, Jr., , M.D. , Ph.D. , Professor , Division 
of Geriatrics, Gerontology and Palliative Medicine in the Department of Medicine.    
 
Contact information: (see next page)  
Dean L. Kellogg, Jr., , M.D., Ph.D. , Professor, Department of Medicine 
Division of Ge riatrics, Gerontology and Palliative Medicine  
University of Texas Health Science Center at San Antonio 7703 Floyd Curl Drive 
Mail Code 7875 
San Antonio, Texas 78229- 3900  
(210) 617- 5197 (phone) â€“ (210) 562 -6130 (fax)  Email: kellogg@uthscsa.edu 
8.5. Unblinding Procedures  
See Section 8.3 â€“ For SAE or SAE- UPIRSO,  the site investigator must report within 24 hours of the event to IND 
Sponsor who confers with Medical Safety Officer  (Section 8. 4) to assess the need for initiation of stopping rules 
or unblinding procedures. Responsibilities of each individual are bulleted below.  
Medical Safety Officer  
â€¢ Assess SAE or SAE- UPIRSO to determine if unblinding is required and, if yes, notify pharmacist to 
request subjectâ€™s assignment  
â€¢ Compare event data to intervention/assignment to determine if SAE is related to study intervention 
â€¢ Assess study and subject safety to determine if stopping rules should be invoked 
â€¢ Create the Safety Officer record in a blinded report format and communicate to Sponsor and with overall 
impression and recommended plan of action 
â€¢ Responsible for determining  the need to â€œunblindâ€ the site investigator  
 
Research Pharmacist  
â€¢ Upon request, if necessary, unblind subject assignment and communicate to Medical Safety Monitor  
â€¢ Suspend dispensing of study drug until SAE reporting is complete  
 
Sponsor  
 
â€¢ Receive  and review Medical Safety Officer report with Pharmacist and Study Statistician  
â€¢ Determine and implement stopping rules by communicating to site investigators, if required  
â€¢ Ensure that IRB, FDA, and funding sponsors are notified as appropriate to local or agency policy  
â€¢ Provide a copy of Medical Safety Officer report/record to appropriate personnel to file in eRegulatory 
Binder   
 
Clinical Study Coordinator  
 
â€¢ Ensure appropriate medical care and follow up is scheduled and implemented until SAE resolved 
8.6. Stopping Rules  
 
In the unlikely event that a study -related death or SAE occurs, the decision to stop the trial, either temporarily 
or permanently, will be the responsibility of the Medical Safety Officer in collaboration with the IND Sponsor.  
 
Clinical excursions that a subject may experience that may warrant stopping study participation or drug administration either temporarily or permanently include but are not limited to:  
 
OXY -SAR-001   Page 19 
Version: 2.5 
0008_Protocol v2.5, 08- 03-18, AMD.docx  
CONFIDENTIAL  
Revised  version: v2.5 08- 03-18 â€¢ Clinical criteria:  
â€“ Fever with a temperature > 101Â°F  or other clinical indication of active illness  
â€“ Blood pressure >170/95 or <90/50  
â€“ Allergic reaction to drug 
â€“ Serious nosebleeds or other localized side effects of drug administration  
â€“ Hyponatremi a (ser um sodium < 135 mmol/L) and/or low serum osmolality (serum osmolality < 275 
mOsm/kg) .  
o Obtain serum sodium levels and osmolality at any time hyponatremia is suspected based on 
symptoms lethargy, muscle spasms, seizures, confusion/delirium, nausea and vomiting or 
physical examination  
o Any patient withdrawn from the study or has low sodium levels at the final visit will be evaluated 
until full normalization of the electrolyte abnormality occurs, and clinical and laboratory evaluations 
will be made available to medical safety monitor for review.  
â€“ Other Serious Adverse Event adjudicated by medical safety monitor and invoking stopping rules  
 
9. Data Handling and Record Keeping  
9.1. Confidentiality  
Information learned about all subjects will be kept confidential.  All data and protected health information (PHI) 
in paper form will be kept confidential by assigned anonymous identifier and kept secured (password protected and/or double locked). Subjects  will not be identified in any way in any publication.   
9.2. Source Documents  
Source data are contained in source documents found in paper subject files at the research site and in site electronic medical records.  If source data are handwritten, print all entries legibly in black ink.  Erasures and white -out material are prohibited. If any entry error has been made on paper, to correct such an error, draw a 
single straight line through the incorrect entry and enter the correct data above it.  All such changes must be initialed and dated.  For clarification of illegible or uncertain entries, print the clarification above the item, then initial and date it.  
9.3. Data Management  
 
Data System: REDCap  
All data will be input using a web front -end interface. All users are individually assigned authorization for access 
to specific components of the database application. Information that is input is checked for logical and range 
consistency and mandatory data fields must be entered in order to input a record. Reports are available as Excel 
exports to each site staff with access to reports.  
 
Case Report Forms  
CRFs will be developed in REDCap and may be printed in PDF for handwritten use.  Radiology and lab reports 
may be printed or copied for use as source documents, while  questionnaires and validated instruments may 
be copied from the Manual of Operations (MOP) for use in the paper research record.  Data entry personnel 
will be appropriately trained before study is initiated. 
9.4. Records Retention  
The IND Sponsor is responsible for maintaining the Trial Master File by way of access to and storage in the 
eRegulatory Binder at Clinical Trials Express.  
 
The local site Principal Investigator is responsible for maintaining study essential documents for at least 3 years 
after study par ticipation ends for the last subject at the last site, or according to the IND Sponsorâ€™s institutional 
OXY -SAR-001   Page 20 
Version: 2.5 
0008_Protocol v2.5, 08- 03-18, AMD.docx  
CONFIDENTIAL  
Revised  version: v2.5 08- 03-18 retention period, whichever is greater.  
 
These documents should be retained for a longer period if required by a funding agency, the FDA or other institutional retention policy .  In such an instance, it is the responsibility of the IND Sponsor to inform the 
investigator/institution as to when these documents no longer need to be retained.  
 
10. Study Monitoring, Auditing, and Inspecting 
10.1.  Study Monitoring Plan 
The Sponsor will ensure that the designated study monitor, compliance specialist or other quality assurance 
reviewer is given access to all the above noted study -related documents and study related facilities (e.g. 
pharmacy, diagnostic laboratory, etc.), and has adequate space to conduct the study monitoring visits.  
 
Monitoring elements will be reviewed at least once during the study period as described below:  
â€¢ Consent process  
â€¢ Accuracy of the collection and processing of laboratory specimens  
â€¢ Forms and source documents in the subjectsâ€™ research records will be current and maintained in a timely 
manner.  
â€¢ Physical and mental condition of the subject and any type of AE will be assessed and monitored prior to beginning the study by the investigator(s) and staff, and during the study period.  
 Areas of focus for study monitoring by the designated study monitor: 
â€¢ Regulatory documentation and compliance with local policy will be monitored once during the study period 
at each site.  
â€¢ The safe handling and accountability of drugs, which includes the use of temperature logs and disposal of waste , will be maintained upon receipt of study drug, upon dispensing,  and at the close out of the study 
period.  
â€¢ Compliance with the protocol and conduct of the study, including the c onsenting process, along with 
source data compared to collected data (SDV), will be monitored once  at each site during the study period.  
â€“ 30% of subject records and 100% of primary outcome data for each subject at each site will be 
monitored.  
â€“ The first and the last subject enrolled will be monitored for consent practices and 100% of eligibility 
data collected.  
â€¢ Adverse event logs will be monitored and research records analyzed for AEs that were overlooked or 
otherwise not documented properly in the study files.  
â€¢ The safety assurance and condition of any electrical, radiological, magnetic, gaseous, and hazardous 
equipment, tools or apparatus that will be used by the investigators and subjects at each site will be 
properly maintained and certified by the siteâ€™s biomedical safety staff on at least an annual basis. The 
local site PI will attest to this assurance prior to enrolling the first subject.  
 
10.2.  Auditing and Inspecting 
The site Investigator will permit study -related monitoring, audits, and inspections by the IRB, the funding 
sponsor, government regulatory bodies, and University compliance groups of all study related documents (e.g. 
source documents, regulatory documents, data collection instruments, study data etc.).  The site investigator will ens ure the capability for inspections of applicable study -related facilities (e.g. pharmacy, diagnostic 
laboratory, etc.).  
 
Participation as a site investigator in this study implies acceptance of potential inspection by government 
OXY -SAR-001   Page 21 
Version: 2.5 
0008_Protocol v2.5, 08- 03-18, AMD.docx  
CONFIDENTIAL  
Revised  version: v2.5 08- 03-18 regulatory authorities and applicable University compliance and quality assurance offices.  
11. Ethical Considerations  
This study is to be conducted according to US and international standards of Good Clinical Practice (FDA Title 
21 part 312) applicable government regulations and Institutional research policies and procedures.  
 
This protocol and any amendments will be submitted to the governing Institutional Review Board (IRB), in agreement with local legal prescriptions, for formal approval of the study conduct.  The decision of t he IRB 
concerning the conduct of the study will be made in writing to the investigator(s) before the study is initiated.  
 
All subjects for this study will be provided a consent form describing this study and providing sufficient information for subjects to make an informed decision about their participation in this study.  See Attachments, Section 15, Attachment  B., Sample Informed Consent Form.  This consent form will be submitted with the 
protocol for review and approval by the IRB for the study.  The formal consent of a subject, using the IRB -
approved consent form, must be obtained before that subject undergoes any study pr ocedure.  The consent 
form must be signed by the subject or legally authorized representative, and the IRB -approved research 
professional obtaining the consent.  
12. Study Finances  
12.1.  Funding Source  
In San Antonio, this study is financed through a grant from the US National Institutes of Health/National Center for Advancing Translational Sciences (NIH/NCATS). Each site is responsible for its own funding of the study, 
including study drug supply.  
12.2.  Conflict of Interest  
None reported (see Forms FDA 3455 on file in CTX  eRegulatory Binder ) 
12.3.  Subject Stipends or Payments  
This study will reimburse subjects for time and transportation.  A schedule of payments is shown below. The 
total potential reimbursement to a subject is $630 for the study for all visits  including both opt ional MRI s ($480 
without MRI) . Payments may be prorated to include the last visit completed if study participation is terminated 
early. Manual payments for additional or partial visits, if necessary, will be handled on an ad -hoc basis with 
prior approval from the funding sponsor. See Payment Schedule in the table below.  
 
Visit 1  $  75 
Visit 2 (optional)  $  75 
Visit 3   $  150 
Visit 4  $  15 
Visit 5 $  30 
Visit 6 $  60 
Visit 7 (optional)  $  75 
Visit 8  $  150 
Manual Payment for an 
Interim Visit Up to $ 30 
 
 
 
OXY -SAR-001   Page 22 
Version: 2.5 
0008_Protocol v2.5, 08- 03-18, AMD.docx  
CONFIDENTIAL  
Revised  version: v2.5 08- 03-18 13. References  
 
 
1. Lawson E, Marengi D, DeSanti R, Holmes T, Schoenfeld D, Tolley C. Oxytocin reduces caloric intake in 
men. Obesity. 2015; 23:950- 956. 
 
2. Zhang H, Wu C, Chen Q, et al. Treatment of obesity and diabetes using oxytocin or analogs in patients 
and mouse models. PLoS ONE. 2013; 8(e61477):1- 11. 
 
3. Borg J, Simren M, Ohlsson B. Oxytocin reduces satiety scores without affecting the volume of nutrient 
intake or gastric emptying rate in healthy subjects. Neurogastroenterol Motil. 2011; 23:56 -e5. 
 
4. Elabd C, Cousin W, Upadhyayula P, et al. Oxytocin is an age -specific circulating hormone that is 
necessary for muscle maintenance and regeneration. Nature Communications. 2014; 5:4082.  
 
5. Meyer -Lindenberg A, Domes G, Kirsch P, Heinrichs M. Oxytocin and vospressin in the human brain: Social 
neuropeptides for translational medicine. Nature Reviews Neuroscience. 2011; 12:524- 538. 
 
6. Leng G, Ludwig M. Intranasal oxytocin: Myths and delusions. Biological Psychiatry. 2016; 79:243 -250. 
 
7. Iwasaki Y, Maejimi Y, Suyama S, et al. Periperal oxytocin activates vagal afferent neurons to suppress 
feeding in normal and leptin- resistant mice: A route for ameliorating hyperphagia and obesity. Am J Physiol 
Regul Integr Comp Physiol. 2015; 308:R360 -R369.  
 
8. Finger E, MacKinley J, Blair M, et al. Oxytocin for frontotemporal dementia: A randomized dose- finding 
study of safety and tolerability. Neurology. 2015; 84:181.  
 
9. Kane R, Shamliyan T, Talley K, Pacala J. The association between geriatric syndromes and survival . J Am 
Geriatr Soc. 2012; 60:896- 904. 
 
10. Kallman D, Plato C, Tobin J. The role of muscle loss in the age -related decline of grip strenth: Cross -
sectional and longitudinal perspectives. Journal of Gerontology: Medical Sciences. 1990; 45:M82- 88. 
 
11. Blau H, Cosgrove B, Ho A. The central role of muscle stem cells in regenerative failure with aging. Nature 
Medicine. 2015; 8:854- 862. 
 
12. Fielding R, Vellas B, Evans W, et al. Sarcopenia; an undiagnosed condition in older adults. current 
consensus definition: Prevalence, etiology, and consequences. international working group on sarcopenia. 
J Am Med Dir Assoc. 2011; 12:249- 256. 
 
13. Matsuda M, DeFronzo RA. Insulin sensitivity indices obtained from oral glucose tolerance testing: Comparison with the euglycemic insulin clamp. Diabetes Care. 1999; 22:1462- 1470.  
 
14. Womble L, Wadden T, Chandler J, Martin A. Agreement between weekly vs. daily assessment of appetite. 
Appetite. 2003; 40:131 -135. 
 
15. Shim J, Oh K, Kim H. Dietary assessment methods in epidemiologic studies. Epidemiology and Health. 2014; 36:e2014009. 
 
16. Ghosh S, Lertwattanarak R, Garduno J, et al. Elevated muscle TLR4 expression and metabolic 
endotoxemia in human aging. Journals of Gerontology: Medical Sciences. 2015; 70:232 -246. 
OXY -SAR-001   Page 23 
Version: 2.5 
0008_Protocol v2.5, 08- 03-18, AMD.docx  
CONFIDENTIAL  
Revised  version: v2.5 08- 03-18  
17. Sriwijitkamol A,  Coletta DK, Wajcberg E, et al. Effect of acute exercise on AMPK signaling in skeletal 
muscle of subjects with type 2 diabetes. Diabetes. 2007; 56:836- 848. 
 
18. Li M, Verdijk LB, Sakamoto K, Ely B, van Loon LJ, Musi N. Reduced AMPK -ACC and mTOR signaling in 
muscle from older men, and effect of resistance exercise. Mechanisms of Ageing & Development. 2012; 
133:655- 664. 
 
19. Snijders T, Verdijk L, Smeets J, et al. The skeletal muscle satellite cell response to a single bout of resistance -type exercise is delayed with aging in men. Age (Dordr). 2014; 36:9699.  
 
20. Billin A, Bantscheff M, Drewes G, et al. Discovery of novel small molecules that activate satellite cell proliferation and enhance repair of damaged muscle. ACS Chem Biol. 2016; 11:518- 529. 
 
21. Husse y SE, Liang H, Costford SR, et al. TAK -242, a small molecule inhibitor of toll- like receptor -4 
signaling, unveils similarities and differences in lipopolysaccharide- and lipid- induced inflammation and 
insulin resistance in muscle cells. Bioscience Reports.  2013; 33:37- 47. 
 
22. MacDonald E, Dadds M, Brennan J, Williams K, Levy F, Cauchi A. A review of safety, side- effects and 
subjective reactions to intranasal oxytocin in human research. Psychoneuroendocrinology. 2011; 36:1114-
1126.  
 
23. Guralnik J, Simonsick E, Ferrucci L, Glynn R, Berkman L, Blazer D, Scherr P, Wallace R. A short physical 
performance battery assessing lower extremity function. Journal of Gerontology; Mar 1994; 49: M85- M94.  
 
24. Podsiadlo D and Richardson S. The timed â€œup and goâ€: a test of basic functional mobility for frail elderly 
persons. J Amer Geriatr Soc; 1991; 39(2): 142 -148. 
 
25. Klopfenstein, B J et al. Comparison of 3 T MRI and CT for the Measurement of Visceral and Subcutaneous 
Adipose Tissue in Humans. Br J Radiol; 2012: 85(1018): e826â€“ e830.
 
 
 
 
14. Attachments  
A. Consent Form Template â€“ page 23  
B. Event Schedule â€“ page 24  
C. Victoria Apotheke Zurich: Syntocinon, Drug information â€“ page 25 
D. Placeholder for Questionnaires, I nstruments  & Forms  â€“ page 26 
E. Summary of Protocol Changes â€“ page 27, 28  
 
     
 
OXY -SAR-001   Page 24 
Version: 2.5 
0008_Protocol v2.5, 08- 03-18, AMD.docx  
CONFIDENTIAL  
Revised  version: v2.5 08- 03-18 ATTACHMENT A.  PLACEHOLDER FOR SAMPLE CONSENT FORM  
 
   
 
     
 
     
 
    
 
     
 
     
 
     
 
    
 
     
 
     
 
OXY -SAR-001   Page 25 
Version: 2.5 
0008_Protocol v2.5, 08- 03-18, AMD.docx  
CONFIDENTIAL  
Revised  version: v2.5 08- 03-18 ATTACHMENT B.  EVENT SCHEDULE  
  Visit 1  Visit 2  Visit 3  Visit 4*  Visit 5  Visit 6  Visit 7  Visit 8  
  Screen  
Day 0  MRI 
+7 days  V2 
+7-14 
days  1 week 
on Rx  4 weeks 
on Rx  6-7.5 
weeks on 
Rx 7-7.5  
weeks 
on Rx 7.5-8 
weeks on 
treatment  
Medical history and physical 
examination, ECG  X               
Vital signs, Weight, BMI,  X    X X  X  X   X 
Waist circumference X    X  X  X   X 
Mini-mental status exam (Mini -
Cog)  X               
Montreal Cognitive 
Assessment (MoCA)  X    X   X 
Geriatric depression scale 
(GDS)  X        
Centers for Epidemiologic 
Studies Depression Scale  X    X   X 
Gait speed, 15 -foot course  X          X     
**Hematology (CBC, HgbA1c) 
and Coagulation testing 
(PT/INR, PTT)  X          X    
**Chemistry with liver function 
and serum osmolality  X    X  X X    
**Lipid Panel  X     X   
**Urinalysis  X               
**Urine osmolality  X      X  X X    
Electrocardiogram  X        
OGTT, 2 hour  X     X   
Body composition (DEXA)     X        X 
Bioimpedance (UTMB only)     X        X 
Calorimetry     X        X 
Randomization    X      
Body composition (MRI)   X X    X  
Functional tests: mSPPB, 
TUG, grip strength   X         X    
24-hour food recall, 3 -day food 
diary, appetite   X    X  X  X    
Muscle biopsy: satellite cell, 
fiber type, fat infiltration, 
inflammation, gene expression     X        X 
Systemic inflammation     X        X 
Drug tolerability/ compliance, 
adverse event monitoring      AE review 
only  X  X X  X 
* After Visit 4, participants may receive periodic phone calls by study staff between study visits to assess any 
symptoms and encourage adherence to study drug.  
** Any marginally abnormal lab findings may be repeated if clinically indicated to ensure initial or continued 
eligibility.  
 
 
OXY -SAR-001   Page 26 
Version: 2.5 
0008_Protocol v2.5, 08- 03-18, AMD.docx  
CONFIDENTIAL  
Revised  version: v2.5 08- 03-18  
 
 
ATTACHMENT C.  PLACEHOLDER FOR VICTORIA APOTHEKE ZURICH  
 
 
 
 
     
 
     
 
    
 
     
 
ATTACHMENT D.  PLACEHOLDER FOR QUESTIONNAIRES, INSTRUMENTS, & FORMS  
    
 
    
 
     
 
     
 
  
 
OXY -SAR-001   Page 27 
Version: 2.5 
0008_Protocol v2.5, 08- 03-18, AMD.docx  
CONFIDENTIAL  
Revised  version: v2.5 08- 03-18 ATTACHMENT E.  SUMMARY OF PROTOCOL CHANGES  
 
Date of Change  Version # Section Modified  Before Change  After Change  
11-21-2016  1.1  Title Page  
 
All pages  
  3.4 Potential Risks  
 
 
 4.2 Exclusion Criteria  
 
 
   
 
    
6.1 Consent and 
Screening Visit 1, page 9  
  
6.3 Visit 3, page 10  
 
  
 
   
 
  6.4 Visit 4, page 11  
   6.5 Visit 5,+4 weeks from 
V4 
   
 
 Section 6, Study Visits  
 
 
8.6, Stopping Rules  IND Number: Pending  
  
 
 Rare: Nausea, dermatitis, uterine 
contractions  
 
Renal disease (Creatinine >1.4)  
    
 
    
Screening labs did not 
include urinalysis, urine or serum osmolality  
 
No safety labs 
mentioned at this visit  
  
 
   
 
  Safety labs: CBC and 
CMP  
 
 Labs: CBC, CMP, 
cholesterol panel, 
HgbA1c, coagulation tests, and systemic inflammatory markers  
 No embedded Visit and Procedures Schedule  
 
No mention of 
hyponatremia or fluid imbalance IND Number: 132460 -0001  
 General spacing, formatting, pagination 
and header/footer changes  
 
(FDA requested change) â€“ Rare: added 
hyponatremia and or fluid imbalance  
 
 
(FDA requested change) Renal disease: 
abnormal serum sodium levels, abnormal urinalysis, or physical exam findings 
indicative of fluid imbalance; individuals with underlying disorder of sodium/water balance, such as SIADH, diabetes 
insipidus, or psychogenic polydipsia;  
Individuals with underlying seizure 
disorder or underlying neurologic disorder that increases seizure risk  
 (FDA requested change) Added 
urinalysis, urine and serum osmolality to 
screening labs  
 (FDA requested change) Visit 3a, 3b, 3c 
created and safety review/labs added at 3c. 
Visit 3a: Blood draw for systemic 
inflammatory markers  
Visit 3b: Optional MRI  
Visit 3c. Safety review/labs: Chemistry, 
including serum sodium and serum 
osmolality and drug tolerability 
assessment  
 
(FDA requested change) Added urinalysis 
and serum osmolality at 4 weeks of drug 
therapy ; removed CBC   
 Assigned safety labs to 6.5.1 Visit 5a â€“ 
Laboratory: CBC, CMP, urinalysis, serum osmolality, lipid panel, HgbA1c, coagulation tests (PT, INR, PTT)  
 
 
Added Table 3, page 13.  
  
(FDA requested change) Added to clinical 
criteria the clinical values for stopping due 
to hyponatremia or changes in fluid 
balance  
OXY -SAR-001   Page 28 
Version: 2.5 
0008_Protocol v2.5, 08- 03-18, AMD.docx  
CONFIDENTIAL  
Revised  version: v2.5 08- 03-18 12-15-16 1.2 Throughout document  
 
Title Page  
  
 
   
 
Table of Contents  
  
3.2 General Study Design  
 
3.4 Potential Risks to Subject Safety  
    
 
 4.3 Subject Recruitment and Screening  
    
 
6.1 Study Procedures  
  
 
  6.2 Baseline  
 
 
   
6.3. 
 
  
6.5  
 
  
 
  10.1, Study Monitoring 
Plan 
  12, Study Finances  
   14, Attachments   
Title of Study: Physiologicalâ€¦  
 Clinical Sites and 
Coordinating Center  
  No Attachment E.  
 Page numbering not hyperlinked  
 
Phase I/II  
 
Blood Withdrawal, page 4 includes details about 
blood being drawn.  
 
IV Lines, page 4: â€¦antecubital vein and a 
hand veinâ€¦  
 
â€¦performed in CRCsâ€¦Subjects will be 
screened for eligibility using an initial phone screen.  
 
 
6.1 Visit 1, Consent and Screening Day 0  
 
  6.2 Baseline  
 
 
   
6.3 Visit 3a.  
 
  
6.5 Visit 5  
 
Table 3. Study Visits and Procedures missing 
a few items  
 
 Areas of focus for study 
monitoringâ€¦  
 
12.3, Subject Stipends or Payments, â€¦total 
potential reimbursement 
of $770  
 Attachments A, B, C, D  
 Formatting and space revisions  
 Changed title of study to â€œPhysiologicâ€   
 Changed UTHSCSA to new brand name 
UTHealth San Antonio  
Added Clinical Trials Expr ess -
Coordinating Center  
Added Attachment E. Summary of 
Protocol Changes  
Added hyperlinks to page numbers  
 
 
Changed to â€œPhase II pilotâ€  
 
Removed detailed lab tests and inserted more general statement that blood will be 
drawn for safety and for research 
purposes at screening and or study visits.  
 Deleted â€œandâ€ and inserted â€œorâ€  
  Changed to read: At some sites, subjects will call- in to an advertised number and 
will be pre- screenedâ€¦callers provide 
permission for research team to follow up with phone screening using an IRB -
approved formâ€¦  
 6.1 Visit 1 (Consent and Screening for Eligibility â€“ Day 0)  
 
Added estimated length of this visit is 5 
hours at the end of paragraph 1.  
 Changed to read Baseline Testing  
 
Moved Grip Strength bullet to fall within 
Functional Testing along with other assessments.  
 
Changed subheading to 6.3 Visit 3a-c: 
Physiological measures, Randomization and optional MRI  
 
Changed subheading to 6.5 Visit 5a-c:  
 
Table 3. Added history and physical, added MMSE , separated blood and urine 
labs into separate rows and visits accordingly  
 Added to 2
nd bullet on drug accountability 
to insert â€œupon dispensingâ€â€¦  
 â€¦changed total to $660 with both MRIs, and $510 without MRIs. Subject payment 
table changed per visit accordingly.  
 
 Changed title of Attachment D  
 
OXY -SAR-001   Page 29 
Version: 2.5 
0008_Protocol v2.5, 08- 03-18, AMD.docx  
CONFIDENTIAL  
Revised  version: v2.5 08- 03-18  
12-15-16 1.2.1    Internal changes only: Incorporated into 
and saved as v1.2 above  
12-19-16 1.2.2  6.1-6.5 Study Procedures   Changed  Visit 1 MMSE to Mini -Cog, 
extended Gait measure from 10 feet to 
15-foot course.  
 Added MoCA to Visit 2   
 Added food and appetite measures at 
Visit 3c and Visit 4 and deleted them at 
Visit 5a .  
 
Modifi ed Visit table accordingly.  
     
12-20-16 
   
 
   1.2.3  ATTACHMENT E. 
Summary of Protocol Changes Table  
 
8.4 Medical Monitor  
 
  
ATTACHMENT B. 
Placeholder for Event Schedule   
   
8.4, Page 16  
 
  
ATTACHMENT 
B., Event Schedule  Updated all changes to date by version 
in the  Summary table.  
  
Added â€œContact Information: (see next 
page)â€ before listing his address, etc. on page 17  
 
Inserted Event Schedule from Page 
12, Table 3, Study Visits and 
Procedures ; corrected event schedule 
in 2 places to be consistent with ICF  
 
03-17-17 1.2.4  Table of Contents  Update Visit Numbers  Renumbered Visit 3a -c, 4, 5a -c to 
visits 3 -9 
  3.1 Definition of Sarcopenic 
Obesity  Updated definition of Sarcopenic 
Obesity to reflect modified consensus. 
Muscle mass will be measured as an 
outcome.  
  6.3-6.5.3  Update Visit Numbers  Renumbered Visit 3a -c, 4, 5a -c to 
visits 3 -9 
  Table 3  Study Visits and 
Procedures  Renumbered Visit 3a-c, 4, 5a -c to 
visits 3 -9 
  Table 12.3  Subject Stipend  Renumbered Visit 3a -c, 4, 5a -c to 
visits 3 -9 
  ATTACHMENT B  ATTACHMENT  B Renumbered Visit 3a -c, 4, 5a -c to 
visits 3 -9 
     
05-16-17 2.0 4.2 Exclusion Criteria  
4.3 
6.1c GDS > 5  GDS > 7  
     
  4.3 Screening tests  Remove ECG  
     
  6.1 Visits 1 and 2  Combined to Visit 1 , remove ECG , 
deleted unnecessary language  
     
  6.1-6.8 Update Visit Numbers  Renumbered Visit 1 -8 
     
  Table 3  Study Visits and  Renumbered Visit 1 -8, removed ECG,  
     
  Table 12.3  Subject Stipend  Renumbered Visit 1 -8 
     
  ATTACHMENT B  ATTACHMENT B  Same as Table 3,  
     
  Summary of Protocol 
Changes Table.   Updated to V2.0 all changes to 
protocol shown abov e 
     
     
OXY -SAR-001   Page 30 
Version: 2.5 
0008_Protocol v2.5, 08- 03-18, AMD.docx  
CONFIDENTIAL  
Revised  version: v2.5 08- 03-18 06-20-17 2.1 6.1 Visit 1  Added ECG back in 
     
  6.2 and 6.3  Visits 2 and 3  Swapped visits 2 and 3 to have 
optional MRI occur before 
randomization. Provided PI discretion 
to forego optional MRI if necessary  
     
  6.3 Visit 3  Baseline visit added to establish IV 
access for biopsy and UT Houston no 
calorimetry due to no equipment.  
     
  6.7 and 6.8  Visits 7 and 8  Swapped visits 7 and 8 to have 
optional MRI occur before completion 
of study drug and final visit  
     
  Visit Table  Visit Table  Swapped visit procedures to be 
consistent with narrative protocol  
     
  Summary of Protocol 
Changes Table   Updated to V2.1 all changes to 
protocol shown for 06 -20-17 version  
     
10-03-17 2.2 Title Page, headers and 
footers  Version number and 
IND series #  Updating version numbering in header 
and footer to 2.2; IND# 0003 = v2.0 protocol, 0004 = v2.1 protocol, 0005 = v2.2 this version to be consistent with 
recent IND reporting to FDA  
     
  Study Summary page 1  Inclusion/Exclusion  Removed ADA criteria from diabetes 
exclusions, using A1c only; changed 
Serum creatinine measure to GFR for 
renal exclusion, changed urinalysis 
criteria for WBC and RBC ; Significant 
heart disease (history of MI within 
the last year or New York Heart 
Classif ication grade III -IV) 
 
  Page 2 and 4   Spacing or format changes  
     
  6.1 Visit 1  Inserted screening window of 30 days  
     
  6.2 and 6.7  Visits 2 and 7  Inserted abdomen to MRI as well as 
dominant lower extremity  
     
  6.3 and 6.8, and Visit table 
page 15  Visits 3 and 8  Changed bioimpedance to be offered 
only at UTMB Galveston  
     
  Reference List  Citation 25  Corrected the reference to MRI of 
abdomen and lower extremity, adding 
citation number 25  
     
10-08-17 2.2.1  Title page and Summary  of 
Changes table  Administrative changes  Added 03 -24-17 as original approval; 
removed â€œ(placeholder)â€™ from CTX address; updated versioning in 
headers and footers  
     
OXY -SAR-001   Page 31 
Version: 2.5 
0008_Protocol v2.5, 08- 03-18, AMD.docx  
CONFIDENTIAL  
Revised  version: v2.5 08- 03-18 10-17-17 2.2.2  Summary of Visits Table  Repeat labs language  Added spaces to create table on single 
page of its own.  
 
Added language to allow repeating marginally abnormal labs if clinically 
indicated to ensure initial or continued 
eligibility  
 Changed periodic phone calls to occur 
after Visit 4  
 
Removed Optional from MRI and 
Baseline from V3  
     
  Title page and footers  Versioning  Updated versioning throughout 
document to 2.2.2.  
     
11-17-17 2.3 Title page and footers  Versioning  Updated versioning throughout 
document to 2.3; IND series -0006 
added to title page  
     
  Visit Section 6 and 
Summary Visit Table  Procedures  Added vital signs to Visits 1,3,4,5,6 
and 8 to narrative section 6  
     
  Visit Section 6.4, 6.5 , 6.6 Labs  Remove lipid panel from Visits 4 and 5  
narrative to be consistent with 
Summary Visit Table.  
 Add urine osmolality to Visit 4 narrative 
to be consistent with other visits 
assessing osmolality and Summary 
Visit Table  
 
Change Visit 4, 5 and 6 referencing 
Visit 2 related to Food Recall to Visit 1.  
     
  Visit Section 6.8  Procedures  Add Vital signs, weight, BMI, MOCA 
and CES -D to narrative to be 
consistent with Summary Visit Table  
     
    Add drug compliance/tolerability, and 
AE review to Visit 8 narrative to be consistent with Summary Visit Table 
 
Add waist circumference to Visit 8 
narrative and to the Summary Table of 
Visits for consistency  
     
  Section 12  12.1 Rephrasing each site responsible for 
its own funding, â€œincluding study drug 
supply.â€  
     
  General   Revised pagination issues throughout 
the document  
     
04-03-18 2.4 Visits 1,3,4,5,6,8 narrative  Fasting state  Revised all visits to be consistent 
whenever there are labs drawn that subject presents to CRC in fasting 
state  
  Visit Schedule  (fasting)  Change table to reflect fasting at Visits 
1,3,4,5,6,8  
  Eligibility criteria  30-40 kg/m2  Change BMI range to 30.0 -43.0 
     
OXY -SAR-001   Page 32 
Version: 2.5 
0008_Protocol v2.5, 08- 03-18, AMD.docx  
CONFIDENTIAL  
Revised  version: v2.5 08- 03-18 08-03-18 2.5 Section 8.3 -8.4 Medical Monitoring  Change Medical Safety Monitor to 
replace A. Fisher with Dean Kellogg, 
MD, PhD  
 
Add oversight by Pepper Center 
DSMB to review study progress and 
overall safety  
     
 